[1]
Ramachandraiah V, Aronow W, Chandy D. Pulmonary sarcoidosis: An update. Postgrad Med 2017; 129(1): 149-58.
[2]
Tana C, Tchernev G, Chokoeva AA, et al. Pulmonary and abdominal sarcoidosis, the great imitators on imaging? Biol Regul Homeost Agents 2016; 30(2)(Suppl. 2): 45-8.
[3]
Chokoeva AA, Tchernev G, Tana M, Tana C. Exclusion criteria for sarcoidosis: A novel approach for an ancient disease? Eur J Intern Med 2014; 25(10)e120
[4]
Al-Harbi A, Al-Otaibi S, Abdulrahman A, et al. Lung granuloma: A clinicopathologic study of 158 cases. Ann Thorac Med 2017; 12(4): 278-81.
[5]
Chokoeva AA, Tchernev G, Tana C, Ananiev J, Wollina U. Sarcoid-like pattern in a patient with tuberculosis. J Biol Regul Homeost Agents 2014; 28(4): 783-8.
[6]
Arar O, Boni F, Meschi T, Tana C. Pulmonary sarcoidosis presenting with miliary opacities. Curr Med Imaging 2019; 15(1): 81-3.
[7]
Scott GC, Berman JM, Higgins JL Jr. CT patterns of nodular hepatic and splenic sarcoidosis: a review of the literature. J Comput Assist Tomogr 1997; 21(3): 369-72.
[8]
Tana C, Dietrich CF, Schiavone C. Hepatosplenic sarcoidosis: Contrast-enhanced ultrasound findings and implications for clinical practice. BioMed Res Int 2014; 2014926203
[9]
Tana C, Iannetti G, D’Alessandro P, Tana M, Mezzetti A, Schiavone C. Pitfalls of contrast-enhanced ultrasound (CEUS) in the diagnosis of splenic sarcoidosis. J Ultrasound 2013; 16(2): 75-80.
[10]
Tana C, Dietrich CF, Schiavone C. Biomed Hepatosplenic sarcoidosis: Contrast-enhanced ultrasound findings and implications for clinical practice. Res Int 2014; 2014926203
[11]
Tana C, Wegener S, Borys E, et al. Challenges in the diagnosis and treatment of neurosarcoidosis. Ann Med 2015; 47(7): 576-91.
[12]
Sgard B, Brillet PY, Bouvry D, et al. Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis. Clin Radiol 2019; 74(1): 81.e9-81.e18.
[13]
Sobic-Saranovic D, Artiko V, Obradovic V. FDG PET imaging in sarcoidosis. Semin Nucl Med 2013; 43(6): 404-11.
[14]
Lu Y, Grant C, Xie K, Sweiss NJ. Suppression of myocardial 18F-FDG uptake through prolonged high-fat, high-protein, and very-low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. Clin Nucl Med 2017; 42(2): 88-94.
[15]
Ricci F, Mantini C, Grigoratos C, et al. The multi-modality cardiac imaging approach to cardiac sarcoidosis. Curr Med Imaging 2019; 15(1): 10-20.
[16]
Bremer W, Sweiss NJ, Lu Y. Serial FDG-PET/CT imaging in the management of cardiac sarcoidosis. Clin Nucl Med 2018; 43(2): e50-2.
[17]
Akaike G, Itani M, Shah H, et al. PET/CT in the diagnosis and workup of sarcoidosis: focus on atypical manifestations. Radiographics 2018; 38(5): 1536-49.
[18]
Aide N, Benayoun M, Kerrou K, Khalil A, Cadranel J, Talbot JN. Impact of [18F]-fluorodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy. Br J Radiol 2007; 80(951): e67-71.
24
2